Paul Hudson is reshaping Sanofi into a modern healthcare company with the ambition to transform the practice of medicine. Paul and the Sanofi teams are focusing efforts to discover, develop, manufacture, and make accessible breakthrough medicines and vaccines for people around the world. Under Paul’s leadership, the company has prioritized social impact, focusing on company culture and putting health and environmental sustainability at the core of its long-term strategy.
Paul joined Sanofi as CEO in September 2019. Previously, Paul was CEO of Novartis Pharmaceuticals from 2016 to 2019. His career in healthcare has spanned the globe, with roles in the US, Japan and Europe. Prior to Novartis, he worked for AstraZeneca, where he held several increasingly senior positions and served as president, AstraZeneca US and executive vice president, North America. He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthélabo UK.
Paul holds a degree in economics from Manchester Metropolitan University in the UK, and in July 2018 his alma mater awarded him an honorary Doctor of Business Administration for his achievements in industry.